

FAQ

Ambu® aScope™ Gastro and Gastro Large Portfolio



Are You Considering Switching to Ambu's Single-Use Gastroscopes?

The Ambu® aScope™ Gastro portfolio is the ideal solution for critical care and surgical endoscopy – and the world's first single-use gastroscopie portfolio. Here are some frequently asked questions about aScope Gastro and aScope Gastro Large.



Q: What sets the aScope Gastro portfolio apart in terms of value?

A: The aScope Gastro portfolio is always ready for use, offering immediate access for endoscopy outside the endoscopy suite. It simplifies post-procedure logistics and reduces the workload of healthcare professionals. It also enhances workflow efficiency, saving you time and money.



Q: Which procedures is the Gastro portfolio best suited for?

A: The Gastro portfolio is ideal for high-risk settings, ensuring consistent performance with a sterile scope ready for use. It is ideal for intraoperative endoscopy, including bariatric, foregut, thoracic, general, and trauma surgeries. It also excels in critical care settings, such as managing upper GI bleeds in the ICU, urgent food impactions, and foreign body removal.



Q: How does aScope Gastro Large differentiate from reusable therapeutic gastroscopes?

A: The aScope Gastro Large features a 4.2 mm working channel, surpassing the 3.7 mm industry standard for reusable therapeutic gastroscopes, and offers 90% higher suction power for efficient operation. With 210 degrees of retroflexion, for EGD procedures, it ensures comprehensive examination and treatment. It is sterile, eliminating the risk of cross-contamination, and made from sustainable bioplastic materials.



Q:

How does single-use improve workflow for surgical and critical care endoscopy?

A:

Single-use gastroscopes eliminate repair and reprocessing costs, logistics, and expensive service contracts. They're also sterile straight from the package. Reusable scopes require complex cleaning processes for high-level disinfection. This results in faster turnaround times, reduces infection risk and increases productivity in high-volume settings. In addition, they streamline operations and provide a cost-effective solution for demanding endoscopy environments.



Q:

What clinical evidence supports the efficacy of the aScope Gastro portfolio?

A:

Clinical evidence is available on the aScope Gastro portfolio landing page on Ambu's website. Examples include studies and posters demonstrating the effectiveness and safety of single-use gastroscopes, such as Endoscopic Submucosal Dissection for Early Gastric Cancer and Gastrointestinal Endoscopy Volume, Efficiency, and Safety Issues.




Q:

What are the GI and surgical communities saying about single-use gastroscopes?

A:

That they enhance workflows for out-of-suite procedures (ICU, OR, especially after-hours) by eliminating reprocessing, which improves staff satisfaction and increases patient throughput. This leads to quicker turnaround times and the ability to perform procedures outside regular hours. Despite initial adjustment challenges, staff surveys indicate increased job satisfaction and reduced stress. Facilities report cost savings and positive patient feedback due to reduced wait times and improved safety.



[Learn More Here](#)

Ambu FOREVER FORWARD

Ambu, Inc.
6721 Columbia Gateway Drive, Suite 200
Columbia, Maryland 21046
Tel. 800 262 8462
Fax 800 262 8673
ambuUSA.com